GlobeNewsWire
25 Aug 2026, 18:50 UTC · 8w ago
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Impact · against what's priced in
The announcement that a law firm is continuing its investigation into Sionna Therapeutics is not a catalyst. The market has already priced in the clinical failure of SION-719 and the subsequent 91.2% stock price crash that triggered the legal scrutiny.
- SION−0.10
No priced-in read yet





